Grzegorz Sukiennicki

Grzegorz Sukiennicki

Auto-generated profile, based on publicly available information

Grzegorz Sukiennicki

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GSGrzegorz Mariusz Sukiennicki
Grzegorz Mariusz Sukiennicki
WMWojciech Marciniak
Wojciech Marciniak
MMMagdalena Muszyńska
Magdalena Muszyńska
PBPiotr Baszuk
Piotr Baszuk
SGSatish Gupta
Satish Gupta
AJAnna Jakubowska
Anna Jakubowska
Lung cancer is the most common adult malignancy accounting for the largest proportion of cancer related deaths. Iron (Fe) is an essential trace element and is a component of several major metabolic pathways playing an important role in many physiological processes. In this study we evaluated the association between Fe concentration in serum, iron metabolism parameters and genetic variaton in 7 genes involved in iron metabolism and anti-oxidative processes with the incidence of lung cancer in Poland. The study included 200 lung cancer patients and 200 matched healthy control subjects. We analyzed serum iron concentration and iron metabolism parameters (TIBC, UIBC, serum ferritin and transferrin saturation), and genotyped seven variants in seven genes: HFE, TFR1, HAMP, TF, SOD2, CAT and GPX1. Lung cancer patients compared to their matched controls had significantly higher mean serum iron level (p = 0.01), ferritin level (p = 0.007) and TIBC (p = 0.006). Analysis revealed that higher concentration of iron and ferritin (IVth quartile) compared to the lower concentration (Ist quartile) was associated with over 2-fold increased lung cancer incidence. We also found that higher transferrin saturation (p = 0.01) and lower TIBC (p<0.01) are associated with better survival of lung cancer patients. The analysis of polymorphisms in iron related genes did not reveal a significant difference between lung cancer patients and controls. However, rs10421768 in HAMP showed a borderline statistically significant correlation with lung cancer risk (OR = 2.83, p = 0.05). The results of this case control study indicate that higher body iron represented by higher Fe and ferritin levels may be associated with lung cancer incidence. Rs10421768 in HAMP may be associated with about 3-times higher lung cancer risk. Higher Fe body content may be associated with better survival of lung cancer patients.

29 April 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MLMarcin R. Lener
Marcin R. Lener
SGSatish Gupta
Satish Gupta
Rodney ScottRodney Scott
Rodney Scott
MTMartin Tootsi
Martin Tootsi
MKMaria Kulp
Maria Kulp
JLJan Lubiński
Jan Lubiński
Selenium has attracted attention because of its antioxidant properties. Antioxidants protects cells from damage. Certain breakdown products of selenium are believed to prevent tumor growth by enhancing the immune cell activity and suppressing the development of tumor blood vessels. In this observational study, selenium level was measured in a series of patients from Poland and Estonia to determine a correlation between levels of this microelement and colorectal cancer risk. A total of 169 colorectal cancer patients and 169 healthy controls were enrolled in the study after obtaining their informed consent. Selenium level in the blood serum was measured using Graphite Furnace Atomic Absorption Spectrometry (GFAAS). The statistical analysis was performed by Fisher’s exact test. The threshold point of selenium level was 55 μg/l and 65 μg/l for Poland and Estonia respectively, for an increase in cancer risk. The lower levels of selenium were associated with greater risk of colorectal cancer. The result reveals a significant strong association between low selenium level and the colorectal cancer risk in both Estonian and Polish populations.

23 December 2019 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
Steven NarodSteven Narod
Steven Narod
THTomasz Huzarski
Tomasz Huzarski
AJAnna Jakubowska
Anna Jakubowska
JGJacek Gronwald
Jacek Gronwald
CCCezary Cybulski
Cezary Cybulski
JLJan Lubiński
Jan Lubiński
Background: Epidemiologic studies have demonstrated a relationship between selenium status and cancer risk among those with low selenium levels. It is of interest to prospectively evaluate the relationship between selenium and cancer among women who reside in a region with ubiquitously low selenium levels. Methods: We performed a nested case-control study of baseline serum selenium levels and cancer risk using data and biological samples from 19,573 females that were participants in a biobanking initiative between 2010 and 2014 in Szczecin Poland. Cases included women with any incident cancer (n = 97) and controls (n = 184) were women with no cancer at baseline or follow-up. Serum selenium was quantified using mass spectroscopy. Results: The odds ratio associated being below the cutoff of 70.0 μg/L compared to a level above 70.0 μg/L was 2.29 (95% CI 1.26–4.19; P = 0.007). The risks for women in the two middle categories were similar and suggests that the normal range be between 70 μg/L and 90 μg/L. There was evidence for an increased risk of cancer among women in the highest category of selenium levels (i.e., > 90 μg/L), but this association did not achieve statistical significance (OR = 1.63; 95%CI 0.63–4.19; P = 0.31). Conclusions: Results from this study suggest that suggest that the optimum serum level of selenium in women living in Poland should be between 70 μg/L and 90 μg/L.

31 July 2020 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
KBKatarzyna Białkowska
Katarzyna Białkowska
WMWojciech Marciniak
Wojciech Marciniak
MMMagdalena Muszyńska
Magdalena Muszyńska
PBPiotr Baszuk
Piotr Baszuk
SGSatish Gupta
Satish Gupta
AJAnna Jakubowska
Anna Jakubowska
Background: Matrix metalloproteinases (MMPs) and metallothioneins (MTs) are Zinc-related proteins which are involved in processes crucial for carcinogenesis such as angiogenesis, proliferation and apoptosis. Several single nucleotide polymorphisms (SNPs) in MMPs and MTs that affect genes expression have been associated with cancer risk, including breast, lung and colon. Methods: The study group consisted of 648 unselected patients (299 with breast cancer, 199 with lung cancer, 150 with colon cancer) and 648 unaffected individuals. Five SNPs, rs1799750 in MMP-1, rs243865 in MMP-2, rs11568818 in MMP-7, rs2252070 in MMP-13 and rs28366003 in MT2A were genotyped and serum zinc (Zn) level was measured. The cancer risk was calculated using multivariable logistic regression with respect to Zn. Results: None of the 5 tested polymorphisms showed a correlation with cancer risk in studied groups, although for MMP-2, MMP-7 and MT2A non-significant differences in genotypes frequencies among cases and controls were observed. Conclusions: Analyses of polymorphisms, rs1799750 in MMP-1, rs243865 in MMP-2, rs11568818 in MMP-7, rs2252070 in MMP-13 and rs28366003 in MT2A in relation to serum Zn level did not show significant association with breast, lung and colon cancer risk among polish patients. Further studies are needed to verify this observation.

12 March 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JLJakub Lubiński
Jakub Lubiński
WMWojciech Marciniak
Wojciech Marciniak
MMMagdalena Muszynska
Magdalena Muszynska
EJEwa Jaworowska
Ewa Jaworowska
MSMieczyslaw Sulikowski
Mieczyslaw Sulikowski
JLJan Lubiński
Jan Lubiński
[This corrects the article DOI: 10.1371/journal.pone.0184873.].

1 January 2012 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
MMMagdalena Muszynska
Magdalena Muszynska
KJKatarzyna Jaworska-Bieniek
Katarzyna Jaworska-Bieniek
KDKatarzyna Durda
Katarzyna Durda
GSGrzegorz Sukiennicki
Grzegorz Sukiennicki
TGTomasz Gromowski
Tomasz Gromowski
JLJan Lubiński
Jan Lubiński
The study was conducted to determine the correlations between serum concentration of arsenic (As) with increased or decreased predisposition to breast and ovarian cancer.